American Vanguard Corporation Q3 FY2025 earnings call

• Adjusted EBITDA increased from $1.8 million in Q3 2024 to $8.2 million in Q3 2025, a over 350% rise. - Gross profit margins grew by 300 basis points. - Optimized manufacturing by transferring production from L.A. to Alabama. - Operating expenses decreased by ~$6 million in Q3 2025 vs Q3 2024 and ~$14 million YTD. - Transformation spend reduced from $8 million to $2 million Q3 2025 vs Q3 2024, expected to be negligible. - Renamed non-crop business to Specialty. - Creating a $100 million net sales medium-term growth portfolio. - Agricultural market has strong U.S. harvest but trade tensions with China cloud over soybean growers; lower channel inventories, decreasing interest rates, China restarting soybean purchases, potential subsidies.

In Q3 2025, U.S. GAAP revenue was $119 million, a 1% increase from $118 million in Q3 2024. The U.S. crop business had mixed performance: herbicides up ~50% and granular soil insecticides up ~5%, but potato market weakness impacted soil fumigant sales. The Specialty business (formerly non-crop) had weakness in horticultural due to product liability early in Q3, but improved later; mosquito adulticide sales were slow. International sales were down due to strategic decisions in Brazil, droughts in Australia, and weather impacts in Central America and Mexico. U.S. GAAP gross profit margin increased to 29% in Q3 2025 from 15% in Q3 2024.

• Full year 2025 adjusted EBITDA target $40 million to $44 million. - Net sales lowered to $520 million to $535 million in 2025. - Expect cost savings to persist, though product development spending in Q4 historically higher but forecasted below last year. - Product liability claims in Specialty expected to be reimbursed.

• Trade tensions with China affecting soybean growers. - Product liability claims in Specialty initially dragging performance but expected to be resolved. - Weather impacts in International markets like droughts in Australia, Central America.

Q: Mike Harrison asks about trends in U.S. crop and Specialty business A: Douglas Kaye responds that U.S. crop was strong with herbicides up, and Specialty product liability was a one-time issue improving.

Q: Wayne Pinsent asks about free cash flow and Corteva's split A: David Johnson talks about free cash flow and Douglas Kaye comments on potential consolidation in market and opportunities for acquisitions.

Q: Charles Rose asks about free cash flow and leverage A: Douglas Kaye discusses EBITDA, CapEx, cash taxes, interest expense, and leverage goals.

Q: Dmitry Silversteyn asks about gross margin improvement and raw materials A: Douglas Kaye attributes gross margin improvement to combination of sales, SIOP process, and manufacturing efficiencies, and says raw material costs are trending down.